Idera Pharmaceuticals (IDRA) Shares are Up 0.52%

Idera Pharmaceuticals (IDRA) : Traders are bullish on Idera Pharmaceuticals (IDRA) as it has outperformed the S&P 500 by a wide margin of 1.72% in the past 4 weeks. The bullishness in the stock continues even in the near-term as the stock has returned an impressive 0.02%, relative to the S&P 500. The stock has continued its bullish performance both in the near-term and the medium-term, as the stock is up 0.52% in the last 1 week, and is up 1.59% in the past 4 weeks. Buying continues as the stock moves higher, suggesting a strong appetite for the stock.

The stock has recorded a 20-day Moving Average of 1.18% and the 50-Day Moving Average is 9.55%.The 200 Day SMA reached 6.67%. Idera Pharmaceuticals, Inc. is up 18.52% in the last 3-month period. Year-to-Date the stock performance stands at -37.86%.


Idera Pharmaceuticals (NASDAQ:IDRA): The stock was completely flat for the day, closing at $1.92 on Friday. The flat closing masks the intraday volatility in the stock. After opening at $1.92, the stock touched an intraday high of $1.94 and a low of $1.87. Neither the bulls nor the bears asserted their supremacy at close, due to which the stock closed completely flat. The stock previously closed at $1.92. The total trading volume on Friday was 150,651.

Idera Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of therapeutics for oncology and rare diseases. The Company uses two drug discovery technology platforms to design and develop drug candidates. Using its Toll-like receptor (TLR) targeting technology, the Company designs synthetic oligonucleotide-based drug candidates to act by modulating the activity of specific TLRs. Using its gene silencing oligonucleotide (GSO) technology, the Company is developing GSOs to turn off the messenger RNA (mRNA) associated with disease causing genes. The Companys drug candidates include IMO-8400 for Waldenstroms macroglobulinemia and diffuse large B-Cell lymphoma; IMO-2055/IMO-2125 for immune-oncology; IMO-8400 for dermatomyositis and Duchenne Muscular Dystrophy (DMD), and IMO-9200 for selected autoimmune disease.

Leave a Reply

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.